Alex Neumeister

BioXcel Therapeutics Executives, Vimal Mehta and Vince O’Neill, discuss how they are actively using artificial intelligence to discover advanced therapies in CNS and oncology.

COO and CMO of BrainStorm, Ralph Kern, discusses how his company is overcoming challenges and advancing science in neurodegenerative disease.

Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.

Dr. Daniel Alkon, President & Chief Science Officer at Neurotrope, discusses novel approaches to AD therapy development and why his company chose to target patients with advanced AD for their own.